MISSISSIPPI DIVISION OF MEDICAID

STANDARDIZED ONE PAGE PHARMACY PRIOR AUTHORIZATION FORM

Mississippi Division of Medicaid, Pharmacy Prior Authorization Unit,
550 High St., Suite 1000, Jackson, MS 39201

☐ **Medicaid Fee for Service**/Change Healthcare
Fax to: 1-877-537-0720 Ph: 1-877-537-0722
https://medicaid.ms.gov/providers/pharmacy/pharmacy-prior-authorization/

☐ **Magnolia Health**/Envolve Pharmacy Solutions
Fax to: 1-877-386-4695 Ph: 1-866-399-0928
https://www.magnoliahealthplan.com/providers/pharmacy.html

☐ **UnitedHealthcare**/OptumRx
Fax to: 1-866-940-7328 Ph: 1-800-310-6826
http://www.uhccommunityplan.com/health-professionals/ms/pharmacy-program.html

☐ **Molina Healthcare**/CVS Caremark
Fax to: 1-844-312-6371 Ph: 1-844-826-4335
http://www.molinahealthcare.com/providers/ms/medicaid/pages/home.aspx

BENEFICIARY INFORMATION

Beneficiary ID: ____ ____ ____ - ____ ____ ____ - ____ ____ ____ | **DOB:** ____ ____ /____ ____ /____ ____ ____ ____

Beneficiary Full Name:

PRESCRIBER INFORMATION

Prescriber's NPI:

Prescriber's Full Name: | **Phone:**

Prescriber's Address: | **FAX:**

PHARMACY INFORMATION

Pharmacy NPI:

Pharmacy Name:

Pharmacy Phone: | **Pharmacy FAX:**

CLINICAL INFORMATION

Requested PA Start Date:_____ **Requested PA End Date:**_____

Drug/Product Requested:_____ **Strength:**_____ **Quantity:**_____

Days Supply:_____ **RX Refills:**_____ **Diagnosis or ICD-10 Code(s):**_____

☐ **Hospital Discharge** ☐ **Additional Medical Justification Attached**

Medications received through coupons and/or samples are not acceptable as justification.

PLEASE COMPLETE AND FAX DRUG SPECIFIC CRITERIA/ADDITIONAL DOCUMENTATION FORM FOUND BELOW

Prescribing provider's signature (signature and date stamps, or the signature of anyone other than the provider, are not acceptable)

I certify that all information provided is accurate and appropriately documented in the patient's medical chart.

Signature required: _____ **Date:** _____

Printed name of prescribing provider:_____

FAX THIS PAGE

CRITERIA/ADDITIONAL DOCUMENTATION

HEPATITIS C *FAX THIS PAGE*

MISSISSIPPI DIVISION OF MEDICAID

BENEFICIARY INFORMATION	
Beneficiary ID:____ ____ ____ - ____ ____ ____ - ____ ____ ____	**DOB:**____ ____ /____ ____ /____ ____ ____ ____
Beneficiary Full Name:	

Hepatitis C Therapy PA Request

Diagnosis / Treatment Status ***(check all that apply)*** ***See Hepatitis-C PA description sheet for approval criteria and intolerance definitions.**

□ Prescriber is, or has consulted with a gastroenterologist, hepatologist, ID specialist or other hepatic specialist. Requires consult within the past year with documentation of recommended regimen.

□ Active HCV infection verified by viral load within the last year: HCV RNA: _____ million IU/mL Date:_____

Genotype verified by lab: □ 1a □ 1b □ 2 □ 3 □ 4 □ 5 □ 6

HIV status: □ positive □ negative (required)

□ Patient has not taken amiodarone within 535 days (required if regimen includes Harvoni or Sovaldi)

□ RBV-Ineligible reason◊: _____

_____

Hepatic fibrosis stage _____

Last stage evaluation date: _____

Method of cirrhosis/fibrosis stage:_____

□ Decompensated cirrhosis

□ Compensated cirrhosis Child-Pugh Score and Date: _____

□ Post-liver transplant Date:

□ Hepatocellular carcinoma and awaiting a liver transplant:

Transplant date: _____

□ Not yet scheduled

□ Dialysis __Yes/____No

□ CrCl ____ mL/min Lab Date w/n last year:_____

□ Screened for HEP-B and HIV prior to HEP-C treatment start

- Date of last test: Hep B:____/__/____ HIV:___/__/____
  - Timing of the screening for Hep-B/HIV should be based on patient specific risk factors but lab result date must be provided and if > 1 year ago, it should be documented in the record as to why repeat testing is not clinically warranted**. If the patient has had ongoing risk factors of any type, consider retesting in the month prior to HCV therapy. If positive, treatment must be considered per AASLD/IDSA and current NIH HIV guidelines.**
  - Repeat screening should be patient specific.

Patient is: □ Treatment naïve □ Relapser

If Relapser, then prior HCV Treatment: last two regimens, if any

Regimen 1: _____ Dates/duration of use: _____ Response: _____

Regimen 2: _____ Dates/duration of use: _____ Response: _____

□ Prior partial responder □ Prior null responder

□ Stopped prior therapy for other reason: _____

Regimen: _____ Dates/duration of use: _____ Response: _____

Social History ***(check all that apply)***

□ Patient is ≥ **18** years of age **OR** meets current AASLD guidelines for treatment

Documentation (available if requested) of:

□ Counseling regarding abstinence from alcohol, IV drug use and education on how to prevent HCV transmission.

□ Abstinence from drugs for at least 6 months; negative urine drug screen required if there is IV drug use history.

For women of childbearing potential and male patients with female partners of childbearing potential ***(for RBV regimens only)*****:**

□ Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment or within 6 months of stopping treatment.

□ Agreement that partners will use 2 forms of effective contraception during treatment and for at least 6 months after stopping tx.

□ Verification that monthly pregnancy tests will be performed throughout treatment.

Other Medications (OTC, Herbal and Prescription) Information

Drug name / strength	Frequency / instructions	Quantity	Refills

PRIOR AUTHORIZATION DESCRIPTION

- *Note annotations and respective definitions as described on* **"Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page**

MISSISSIPPI DIVISION OF MEDICAID

Hepatitis C Therapy PA Request
Guidelines for Regimen Selection and Definitions

For beneficiaries meeting the criteria, the Mississippi Division of Medicaid (DOM) will approve Hepatitis C treatment PA requests as follows:

- The regimens listed for each clinical scenario below are the preferred regimens for MS Medicaid beneficiaries, based on clinical and cost considerations and are consistent with AASLD/IDSA guidelines. http://www.hcvguidelines.org/full-report-view

OR

- **Pediatric formulations of direct acting antivirals (DAA) with FDA approval will be approved for those patients under the age of eighteen when used according to the table below for treatment naïve children as well as in accordance with current AASLD guidelines including for indication and age - Prior authorization is still required prior to the first dose.**

GT	Age (years)	Weight (kg)	Drug	Dose	Weeks
Any	3 to 11	< 20	Mavyret Oral Pellets	Three 50 mg/20 mg packets daily	8
		20 - <30	Mavyret Oral Pellets	Four 50 mg/20 mg packets daily	8
		30 - < 45	Mavyret Oral Pellets	Five 50 mg/20 mg packets daily	8
		45+	Mavyret Tablets	Three 100/40 tablets daily	8
	12+		Mavyret Tablets	Three 100/40 tablets daily	8
	≥ 6	≥ 30	sofosbuvir/velpatasvir 400/100 tablet	One tablet daily	12

OR

- *Clinical rationale is provided for using a regimen that is beyond those within the current guidelines, or for selecting regimens using non-preferred drugs on the Mississippi Division of Medicaid Universal Preferred Drug List*

On the PA Request Form, which must be approved prior to the 1st dose, document the clinical condition supporting the requested regimen. Unless otherwise specified, you do not need to attach documentation to the form. You are attesting to the fact that documentation is available in the patient chart for all information you provide.

DEFINITIONS/ANNOTATIONS USED ON PA FORM:

▽ **Low Dose Ribavirin = 600 mg/day and increase as tolerated**

◊ **Ribavirin-Ineligible** (documentation exists in the patient's chart for at least one of the following):

- Hypersensitivity to RBV
- History of severe or unstable cardiac disease
- Pregnant women and men with pregnant partners
- Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)
- Baseline platelet count < 70,000 cells/mm3
- ANC < 1500 cells/mm3
- Hb < 12 gm/ml in women or <13 g/dl in men

RENAL DYSFUNCTION Patients with CrCl <50 ml/mm should not be treated with ribavirin.

PRIOR AUTHORIZATION DESCRIPTION

- *Note annotations and respective definitions as described on* **"Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page**

MISSISSIPPI DIVISION OF MEDICAID

Preferred Direct Acting Antivirals
Mavyret (glecaprevir/pibrentasvir) 300/120 mg
sofosbuvir/velpatasvir 400/100 mg

Pediatric Indicated Direct Acting Antiretrovirals (FDA approved age ranges and indications ONLY)
Mavyret (glecaprevir/pibrentasvir) 400/100 mg
Mavyret Oral Pellets (glecaprevir/pibrentasvir) 50/20mg
Epclusa 200/50 mg tablet
Harvoni (ledipasvir/sofosbuvir) 45/200 mg tablet
Harvoni (ledipasvir/sofosbuvir) 90/400 mg tablet
Harvoni 33.75/150 mg pellet pak
Harvoni 45/200 mg pellet pak
Sovaldi (sofosbuvir) 200 mg
sofosbuvir/velpatasvir 400/100 mg

Non-Preferred Direct Acting Antivirals
Harvoni (ledipasvir/sofosbuvir) 90/400 mg
Sovaldi (sofosbuvir) 400 mg
ledipasvir/sofosbuvir 90/400 mg
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)
Epclusa (sofosbuvir/velpatasvir) 400/100 mg

Preferred (most cost-effective) Regimens Listed Below*. Not all available regimens are listed.*

NOTE: Adult Guidelines have changed substantially; most recommendations are largely genotype non-specific; exceptions are noted in red

PLEASE CHECK REQUESTED REGIMEN

ADULT: Treatment naïve

No cirrhosis

- ❑ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks (for GT5/6 and/or HIV/HCV co-infection, 12 weeks is recommended)
- ❑ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks

Compensated cirrhosis, HIV negative

- ❑ Mavyret 100/40 mg, three (3) tablets daily for 8 weeks
- ❑ sofosbuvir/velpatasvir 400/100, one tablet daily for 12 weeks (for GT3, add weight based RBV if Y93H positive)

Compensated cirrhosis, HIV positive

- ❑ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks
- ❑ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks (for GT3, add weight based RBV if Y93H positive)

ADULT: Treatment experienced (with or without compensated cirrhosis)

Sofosbuvir-based regimen

- ❑ Mavyret 100/40 mg, three (3) tablets daily for 16 weeks

NS3/4 protease inhibitor inclusive regimen (e.g. Zepatier)

- ❑ Vosevi 400/100/100 mg, one tablet daily for 12 weeks

Mavyret

- ❑ Vosevi 400/100/100 mg, one tablet daily for 12 weeks (if compensated cirrhosis, add weight based RBV)

Vosevi or sofosbuvir + Mavyret

PRIOR AUTHORIZATION DESCRIPTION

- *Note annotations and respective definitions as described on "*Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page

MISSISSIPPI DIVISION OF MEDICAID

❑ Vosevi 400/100/100 mg, one tablet daily + weight based RBV for 24 weeks

GT 3 only: sofosbuvir/NS5A (e.g. Harvoni)

❑ Vosevi 400/100/100 mg, one tablet daily + weight based RBV for 12 weeks

ADULT: Re-infection of Allograft Liver after Transplant

DAA-treatment naïve, no decompensated cirrhosis

❑ Mavyret 100/40 mg, three (3) tablets daily for 12 weeks

❑ sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks

DAA-treatment experienced, no decompensated cirrhosis

❑ Vosevi 400/100/100 mg, one tablet daily for 12 weeks

IF multiple negative baseline characteristics, consider

❑ Vosevi 400/100/100 mg, one tablet daily + low dose RBV for 12 weeks

Treatment naïve, decompensated cirrhosis

❑ sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 12 weeks

Treatment experienced, decompensated cirrhosis (Child-Pugh B or C ONLY)

❑ sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 24 weeks

ADULT: Decompensated Cirrhosis

No prior sofosbuvir or NS5A failure

❑ sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 12 weeks (low dose RBV recommended for Child-Pugh class C cirrhosis)

❑ sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for RBV)

Prior sofosbuvir or NS5A failure

❑ sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 24 weeks (low dose RBV if Child-Pugh C)

Other Treatment Regimen requested

Genotype, treatment history, and extent of liver disease:

_____

_____

Drug names, doses and

durations:_____

_____

Clinical rationale for selecting regimens other than those outlined above:

_____

_____

PRIOR AUTHORIZATION DESCRIPTION

- ***Note annotations and respective definitions as described on "*Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page**

For unique patient populations with renal impairment or HIV: please refer to the current AASLD Guidelines for recommended treatments. http://www.hcvguidelines.org/full-report-view

If HIV positive: Please refer to the current AASLD Guidelines for potential drug interactions and recommended dosing adjustments.

DRUG INTERACTIONS

Reference: http://hep-druginteractions.org/ provides clinically useful, reliable, and current evidence-based information on relevant drug interactions with hepatitis medications.